Company: CERO
Filing Date: 2025-12-05
Form Type: S-1
Source: 0001213900-25-118817
Chunk: 393

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-05
Form: S-1
Chunk 393
---
 
 - 
 - 
 - |     | Additional 
 Paid-in    
 Capital    |   929,464 
     5,766 
    96,896 
         - 
 1,032,126 
     4,431 
         - |     | Accumulated 
 Deficit     | (35,800,244 
 -           
 -           
 (7,289,577  
 (43,089,821 
 -           
 (572,211    | ) 
 ) 
 ) 
 ) |     | Total         
 Stockholders’ 
 Deficit       | (34,870,780 
 5,766       
 96,896      
 (7,289,577  
 (42,057,695 
 4,431       
 (572,211    | ) 
 ) 
 ) 
 ) |
|:-----------------------------------------------|:----|:----------------|----------:|:----|:-------|----------:|:----|:-------|-----------:|:----|:-------|-----------:|:----|:-------|----:|:----|:-------|:--|:----|:-----------|----------:|:----|:------------|:------------|:--|:----|:--------------|:------------|:--|
| Balance                                        
 at February 13, 2024 (Predecessor)             |     |                 | 5,155,703 |     | $      | 4,077,560 |     |        | 22,764,764 |     | $      | 38,023,784 |     |        | 292 |     | $      | - |     | $          | 1,036,557 |     | $           | (43,662,032 | ) |     | $             | (42,625,475 | ) |

See accompanying notes to the consolidated financial statements Reflects a 1-for-100 reverse stock split effective January 8, 2025 and a 1-for-20 reverse stock split effective June 13, 2025 F-38 CERO THERAPEUTICS HOLDINGS, INC. CONSOLIDATED STATEMENTS OF CASH FLOW

|                                                                                              |     | For the      
 period from  
 February 14, 
 2024 through 
 December 31, 
 2024         |             |   |     | For the      
 period from  
 January 1,   
 2024 through 
 February 13, 
 2024         |